Pharmacokinetics of intravenous cyclosporine in bone marrow transplant patients: Comparison of two assay methods

Gary C. Yee, Michael S. Kennedy, Rainer Storb, E. Donnall Thomas

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The influence of assay method on steady-state cyclosporine (CsA) pharmacokinetics was studied in 18 patients with leukemia or aplastic anemia undergoing allogeneic marrow transplantation who received i.v. CsA for prophylaxis or treatment of graft-versus-host disease. Since CsA is extensively metabolized and subject to biliary elimination, CsA courses were divided according to the presence (serum bilirubin > 2.0 mg/dl) or absence (serum bilirubin ≤ 1.2 mg/dl) of hepatic dysfunction. All patients had normal renal function. Serum CsA concentrations were measured concurrently by radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC). Serum concentration-time data were analyzed by standard nonlinear regression methods. Systemic clearance (CI2) calculated from HPLC results was higher than that derived from RIA results, regardless of hepatic function (P < 0.05). These data indicate that results obtained by RIA overestimate CSP concentrations, presumably because of the presence of crossreactive CSP metabolites. These differences can significantly affect derived pharmacokinetic parameters. Therefore, clinicians who make dosage recommendations based on pharmacokinetic parameters should consider the effect of assay method.

Original languageEnglish (US)
Pages (from-to)511-513
Number of pages3
JournalTransplantation
Volume38
Issue number5
DOIs
StatePublished - Nov 1984

Fingerprint

Cyclosporine
Pharmacokinetics
Bone Marrow
Radioimmunoassay
Transplants
Serum
Bilirubin
High Pressure Liquid Chromatography
Aplastic Anemia
Liver
Homologous Transplantation
Graft vs Host Disease
Leukemia
Kidney
Therapeutics

ASJC Scopus subject areas

  • Transplantation

Cite this

Pharmacokinetics of intravenous cyclosporine in bone marrow transplant patients : Comparison of two assay methods. / Yee, Gary C.; Kennedy, Michael S.; Storb, Rainer; Thomas, E. Donnall.

In: Transplantation, Vol. 38, No. 5, 11.1984, p. 511-513.

Research output: Contribution to journalArticle

Yee, Gary C. ; Kennedy, Michael S. ; Storb, Rainer ; Thomas, E. Donnall. / Pharmacokinetics of intravenous cyclosporine in bone marrow transplant patients : Comparison of two assay methods. In: Transplantation. 1984 ; Vol. 38, No. 5. pp. 511-513.
@article{f90279bcbb2d4b398a6648dca86cbe3f,
title = "Pharmacokinetics of intravenous cyclosporine in bone marrow transplant patients: Comparison of two assay methods",
abstract = "The influence of assay method on steady-state cyclosporine (CsA) pharmacokinetics was studied in 18 patients with leukemia or aplastic anemia undergoing allogeneic marrow transplantation who received i.v. CsA for prophylaxis or treatment of graft-versus-host disease. Since CsA is extensively metabolized and subject to biliary elimination, CsA courses were divided according to the presence (serum bilirubin > 2.0 mg/dl) or absence (serum bilirubin ≤ 1.2 mg/dl) of hepatic dysfunction. All patients had normal renal function. Serum CsA concentrations were measured concurrently by radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC). Serum concentration-time data were analyzed by standard nonlinear regression methods. Systemic clearance (CI2) calculated from HPLC results was higher than that derived from RIA results, regardless of hepatic function (P < 0.05). These data indicate that results obtained by RIA overestimate CSP concentrations, presumably because of the presence of crossreactive CSP metabolites. These differences can significantly affect derived pharmacokinetic parameters. Therefore, clinicians who make dosage recommendations based on pharmacokinetic parameters should consider the effect of assay method.",
author = "Yee, {Gary C.} and Kennedy, {Michael S.} and Rainer Storb and Thomas, {E. Donnall}",
year = "1984",
month = "11",
doi = "10.1097/00007890-198411000-00014",
language = "English (US)",
volume = "38",
pages = "511--513",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetics of intravenous cyclosporine in bone marrow transplant patients

T2 - Comparison of two assay methods

AU - Yee, Gary C.

AU - Kennedy, Michael S.

AU - Storb, Rainer

AU - Thomas, E. Donnall

PY - 1984/11

Y1 - 1984/11

N2 - The influence of assay method on steady-state cyclosporine (CsA) pharmacokinetics was studied in 18 patients with leukemia or aplastic anemia undergoing allogeneic marrow transplantation who received i.v. CsA for prophylaxis or treatment of graft-versus-host disease. Since CsA is extensively metabolized and subject to biliary elimination, CsA courses were divided according to the presence (serum bilirubin > 2.0 mg/dl) or absence (serum bilirubin ≤ 1.2 mg/dl) of hepatic dysfunction. All patients had normal renal function. Serum CsA concentrations were measured concurrently by radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC). Serum concentration-time data were analyzed by standard nonlinear regression methods. Systemic clearance (CI2) calculated from HPLC results was higher than that derived from RIA results, regardless of hepatic function (P < 0.05). These data indicate that results obtained by RIA overestimate CSP concentrations, presumably because of the presence of crossreactive CSP metabolites. These differences can significantly affect derived pharmacokinetic parameters. Therefore, clinicians who make dosage recommendations based on pharmacokinetic parameters should consider the effect of assay method.

AB - The influence of assay method on steady-state cyclosporine (CsA) pharmacokinetics was studied in 18 patients with leukemia or aplastic anemia undergoing allogeneic marrow transplantation who received i.v. CsA for prophylaxis or treatment of graft-versus-host disease. Since CsA is extensively metabolized and subject to biliary elimination, CsA courses were divided according to the presence (serum bilirubin > 2.0 mg/dl) or absence (serum bilirubin ≤ 1.2 mg/dl) of hepatic dysfunction. All patients had normal renal function. Serum CsA concentrations were measured concurrently by radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC). Serum concentration-time data were analyzed by standard nonlinear regression methods. Systemic clearance (CI2) calculated from HPLC results was higher than that derived from RIA results, regardless of hepatic function (P < 0.05). These data indicate that results obtained by RIA overestimate CSP concentrations, presumably because of the presence of crossreactive CSP metabolites. These differences can significantly affect derived pharmacokinetic parameters. Therefore, clinicians who make dosage recommendations based on pharmacokinetic parameters should consider the effect of assay method.

UR - http://www.scopus.com/inward/record.url?scp=0021675727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021675727&partnerID=8YFLogxK

U2 - 10.1097/00007890-198411000-00014

DO - 10.1097/00007890-198411000-00014

M3 - Article

C2 - 6388073

AN - SCOPUS:0021675727

VL - 38

SP - 511

EP - 513

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 5

ER -